利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

239 条记录 (耗时 0.067 秒)

    Preventive and/or therapeutic agent of cartilage disorder
    2.
    发明专利
    Preventive and/or therapeutic agent of cartilage disorder 审中-公开
    预防和/或治疗药物治疗药物

    公开(公告)号：JP2014166993A

    公开(公告)日：2014-09-11

    申请号：JP2014016928

    申请日：2014-01-31

    申请人： Ono Pharmaceut Co Ltd ,  小野薬品工業株式会社

    发明人： OBITSU TETSUO ,  TANI KOSUKE ,  SUGIHARA HIKARI ,  NISHIURA AKIO ,  FUJIMURA SHINSEI

    IPC分类号： A61K31/5575 ,  A61K31/07 ,  A61K31/557 ,  A61K31/59 ,  A61K31/728 ,  A61K38/00 ,  A61K45/00 ,  A61K47/40 ,  A61K47/48 ,  A61P19/00 ,  A61P19/02 ,  A61P19/08 ,  A61P27/16 ,  A61P29/00

    摘要： PROBLEM TO BE SOLVED: To provide a cartilage disorder preventive and/or therapeutic agent with the general formula (A) being an active body, allowing infusion into an articular cavity as a disease affected part in order to improve cartilage disorders with expressing no adverse effect and staying in the articular cavity to continuously exhibit drug efficacy.SOLUTION: A compound represented by the general formula (I) (where all symbols are as described in the specification), a solvate thereof or a cyclodextrin inclusion complex thereof expresses no adverse effects of a circulatory system even if such an amount to exhibit cartilage regeneration action is administered, so it is very useful as a safe and effective cartilage disorder preventive and/or therapeutic agent. In addition, a pharmaceutical composition containing a compound represented by the general formula (I), a solvate thereof, or a cyclodextrin inclusion complex thereof can be infused without incising an affected part so the burden of a patient can be mitigated, and thus it is very useful.

    摘要翻译： 要解决的问题：提供具有通式（A）作为活性体的软骨障碍预防和/或治疗剂，允许作为疾病影响部位输注到关节腔中，以改善软骨疾病，表达无不良反应 并保持在关节腔中以连续显示药物效力。溶液：由通式（I）表示的化合物（其中所有符号如说明书所述），其溶剂合物或环糊精包合物复合物不表现出不利影响 即使施用显示软骨再生作用的量的循环系统，因此作为安全有效的软骨障碍预防和/或治疗剂是非常有用的。 此外，含有通式（I）表示的化合物，其溶剂化物或其环糊精包合物的药物组合物可以不影响患处而输入，能够缓解患者的负担， 很有用。

    Compound containing basic group and use thereof
    4.
    发明专利
    Compound containing basic group and use thereof 审中-公开
    包含基本组合的化合物及其用途

    公开(公告)号：JP2013032397A

    公开(公告)日：2013-02-14

    申请号：JP2012248824

    申请日：2012-11-12

    申请人： Ono Pharmaceut Co Ltd ,  小野薬品工業株式会社

    发明人： KOKUBO MASAYA ,  TANAKA MOTOYUKI ,  OCHIAI HIROSHI ,  TAKAOKA YOSHIKAZU ,  SHIBAYAMA SHIRO

    IPC分类号： C07D471/10 ,  A61K31/438 ,  A61K45/00 ,  A61P11/00 ,  A61P19/02 ,  A61P27/02 ,  A61P29/00 ,  A61P31/18 ,  A61P35/00 ,  A61P35/04 ,  A61P37/06 ,  A61P43/00

    CPC分类号： A61K31/695 ,  A61K31/4178 ,  A61K31/435 ,  A61K31/5377 ,  A61K45/06 ,  C07D233/64 ,  C07D471/10 ,  C07F7/1844

    摘要： PROBLEM TO BE SOLVED: To provide a novel compound containing a basic group, which is useful as a medicine, and to provide a use thereof.SOLUTION: The compound is represented by formula (I), (wherein J represents a crosslinked cyclic group which may be substituted by a basic group-containing group and further which may have a substituent, and other symbols are not described). This compound, a salt thereof, a solvent thereof or a prodrug thereof has an antagonistic activity against CXCR4 and is therefore useful as: a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, rejection of transplanted organ, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.); or an agent for regeneration therapy and the like.

    摘要翻译： 待解决的问题：提供一种可用作药物的含有碱性基团的新型化合物，并提供其用途。 解决方案：该化合物由式（I）表示，（其中J表示可以被含碱性基团取代并且可以具有取代基的交联的环状基团，其他符号未被描述）。 该化合物，其盐，其溶剂或其前体药物对CXCR4具有拮抗作用，因此可用作：CXCR4介导的疾病的预防和/或治疗剂，例如炎症和免疫疾病（例如， 类风湿关节炎，关节炎，视网膜病变，肺纤维化，移植器官排斥反应等），过敏性疾病，感染（例如人类免疫缺陷病毒感染，获得性免疫缺陷综合征等），精神神经病，脑疾病，心血管疾病，代谢 疾病和癌性疾病（例如癌症，癌症转移等）; 或再生治疗剂等。 版权所有（C）2013，JPO＆INPIT

    Preparation for injection containing sivelestat sodium salt or hydrate thereof
    6.
    发明专利
    Preparation for injection containing sivelestat sodium salt or hydrate thereof 有权
    含有SODELESTAT SODIUM盐或其水合物的注射剂的制备

    公开(公告)号：JP2012188421A

    公开(公告)日：2012-10-04

    申请号：JP2012038167

    申请日：2012-02-24

    申请人： Ono Pharmaceut Co Ltd ,  小野薬品工業株式会社

    发明人： MAMIYA RYO ,  NAKAI TAKUYA

    IPC分类号： A61K31/222 ,  A61K9/08 ,  A61K9/19 ,  A61K47/02 ,  A61K47/10 ,  A61P11/00 ,  A61P43/00

    摘要： PROBLEM TO BE SOLVED: To provide a preparation for an injection containing a sivelestat sodium salt and a hydrate thereof, improving solubility in a solution at a low temperature, and/or allowing maintenance of a clear solution state without being accompanied with a change in formulation even under preservation over a long period of time when formulated with a transfusion.SOLUTION: The preparation for the injection containing sivelestat sodium salt and a hydrate thereof, and a hydrogencarbonate is a preparation having improved solubility in the solution at the low temperature, and further a preparation maintaining the clear solution state without being accompanied with the change in formulation even after the lapse of a long period of time under formulation with the transfusion. The preparation is an extremely readily handleable preparation in medical practices.

    摘要翻译： 待解决的问题：为了提供含有唾液乳酸钠盐及其水合物的注射剂的制备，提高在低温下溶液中的溶解度和/或允许维持澄清溶液状态而不伴随着 即使在输血配制的情况下长时间保存也能改变配方。 解决方案：含有唾液乳酸钠盐及其水合物和碳酸氢盐的注射剂的制备是在低温下在溶液中具有改善的溶解性的制剂，并且还有一种保持澄清溶液状态而不伴随着 即使经过长时间的配制，输血也改变了。 这种准备是医疗实践中非常容易处理的准备工作。 版权所有（C）2013，JPO＆INPIT

    Extracellular region multimer of cell surface functional molecule
    7.
    发明专利
    Extracellular region multimer of cell surface functional molecule 有权
    细胞表面功能分子的细胞外区域多样性

    公开(公告)号：JP2012157357A

    公开(公告)日：2012-08-23

    申请号：JP2012067720

    申请日：2012-03-23

    申请人： Ono Pharmaceut Co Ltd ,  小野薬品工業株式会社

    发明人： MINATO NAGAHIRO ,  TANAKA YOSHIMASA ,  SHIBAYAMA SHIRO

    IPC分类号： C12N15/09 ,  A61K38/00 ,  A61K45/00 ,  A61P31/00 ,  A61P35/00 ,  A61P35/04 ,  A61P37/04 ,  A61P43/00 ,  C07K14/705 ,  C07K19/00 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10

    CPC分类号： C07K14/70503 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/00 ,  A61K47/26 ,  C07K14/70532

    摘要： PROBLEM TO BE SOLVED: To provide a substance which has specificity and activity and effectivity the same as or more than antibodies as a substance pharmaceutically controlling the functions of a cell surface functional molecule, and which dose not require high grade production technology and equipments for converting the substance to a medicine.SOLUTION: There are provide multimers of an extracellular region of cell surface functional molecules especially extracellular region tetramers of PD-1 or PD-L1. Further, there are provided uses of the tetramers as a preventive and/or therapeutic agent for cancer or cancer metastasis, and immunodeficiency, infectious disease or the like, and uses as an examination or diagnostic agent or a research reagent of the diseases of the PD-1 or PD-L1.

    摘要翻译： 要解决的问题：提供具有特异性，活性和有效性等于或大于作为药物控制细胞表面功能分子的功能的物质的物质，并且其不需要高级生产技术， 将物质转化为药物的设备。 解决方案：提供细胞表面功能分子细胞外区域的多聚体，特别是PD-1或PD-L1的胞外区四聚体。 此外，提供四聚体作为癌症或癌症转移的预防和/或治疗剂，免疫缺陷，感染性疾病等的用途，以及作为PD的疾病的检查或诊断剂或研究试剂的用途 -1或PD-L1。 版权所有（C）2012，JPO＆INPIT

    Percutaneous absorption type preparation
    8.
    发明专利
    Percutaneous absorption type preparation 审中-公开
    PERCUTANEOUS吸收式制备

    公开(公告)号：JP2012126739A

    公开(公告)日：2012-07-05

    申请号：JP2012070208

    申请日：2012-03-26

    申请人： Kyorin Pharmaceutical Co Ltd ,  Ono Pharmaceut Co Ltd ,  小野薬品工業株式会社 ,  杏林製薬株式会社

    发明人： TAKAHASHI KOICHI ,  SAKAI YOSHINORI

    IPC分类号： A61K31/4164 ,  A61K9/70 ,  A61K47/06 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/16 ,  A61K47/22 ,  A61K47/32 ,  A61K47/34 ,  A61P1/04 ,  A61P11/00 ,  A61P11/06 ,  A61P13/10

    CPC分类号： A61K9/7053 ,  A61K9/7069 ,  A61K31/4164

    摘要： PROBLEM TO BE SOLVED: To provide a percutaneous absorption type preparation which comprises 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide as the active ingredient and a backbone for transdermal system, and satisfies at lest one of the following conditions (1) and (2).SOLUTION: The phermaceutical preparation enables absorption of 4-(2-methyl-1-imidazolyl)-2.2-dephenylbutylamide, which has a low ability to be absorbed from the skin, from the skin into the body continuously and efficiently. (1) The active ingredient content in one preparation or one time administration preparation is from about 0.1 mg to about 10 mg, (2) the size is from about 1 cmto about 300 cm.

    摘要翻译： 待解决的问题：提供一种包含4-（2-甲基-1-咪唑基）-2,2-二苯基丁基酰胺作为活性成分的经皮吸收型制剂和经皮系统的骨架，并满足至少一个 的条件（1）和（2）。 解决方案：药物制剂使得能够连续有效地从皮肤吸收具有低于皮肤吸收能力的4-（2-甲基-1-咪唑基）-2,2-脱苯基丁酰胺。 （1）一次制剂或一次给药制剂中的活性成分含量为约0.1mg至约10mg，（2）尺寸为约1cm至约1cm 300厘米 2 。 版权所有（C）2012，JPO＆INPIT

    Prevention and/or treating method of neurodegenerative diseases
    9.
    发明专利
    Prevention and/or treating method of neurodegenerative diseases 审中-公开
    预防和/或治疗神经源性疾病的方法

    公开(公告)号：JP2012046543A

    公开(公告)日：2012-03-08

    申请号：JP2011256936

    申请日：2011-11-25

    申请人： Ono Pharmaceut Co Ltd ,  小野薬品工業株式会社

    发明人： FUNAKOSHI YOSUKE ,  MIZUSHIMA TAKESHI ,  TAKAKUWA HISAO

    IPC分类号： A61K31/19 ,  A61K31/20 ,  A61K47/02 ,  A61P9/10 ,  A61P25/28 ,  A61P43/00

    CPC分类号： A61K47/02 ,  A61K9/0019 ,  A61K31/195 ,  A61K31/20 ,  A61K2300/00

    摘要： PROBLEM TO BE SOLVED: To provide a drug for treatment of neurodegenerative diseases.SOLUTION: Provided are a prevention and/or a parenteral drug containing (2R)-2-propyl octanic acid or its salt for treatment of a neurodegenerative disease, a nervous disorder, and a disease requiring a nerve regeneration. This therapy is characterized by dosing parenterabout 100 mg or more of the drug per each administration, and is useful for the prevention and/or treatment of neurodegenerative diseases including cerebral infarction, since it has an improvement effect on the nervous disorder and an increase suppressing effect on S 100 βin cerebral infarction cases. Moreover, the drug is useful also as a nerve regeneration agent after transplantaton.

    摘要翻译： 待解决的问题：提供治疗神经变性疾病的药物。 解决方案：提供含有（2R）-2-丙基辛酸或其盐的预防和/或肠胃外药物，用于治疗神经变性疾病，神经障碍和需要神经再生的疾病。 该疗法的特征在于每次给药不服药100mg或更多的药物，并且可用于预防和/或治疗包括脑梗塞在内的神经变性疾病，因为它对神经障碍有改善作用和增加抑制作用 在S100脑梗死病例中。 此外，该药物也可用作移植后的神经再生剂。 版权所有（C）2012，JPO＆INPIT

    Pharmaceutical composition for treatment of disease due to vascular constriction or vasodilation
    10.
    发明专利
    Pharmaceutical composition for treatment of disease due to vascular constriction or vasodilation 有权
    用于治疗由血管扩张或血管扩张引起的疾病的药物组合物

    公开(公告)号：JP2012031201A

    公开(公告)日：2012-02-16

    申请号：JP2011239881

    申请日：2011-11-01

    申请人： Ono Pharmaceut Co Ltd ,  小野薬品工業株式会社

    发明人： NAKADE SHINJI ,  SUZUKI HIDEHIRO ,  HABASHITA HIROSHI

    IPC分类号： C07D211/48 ,  A61K31/437 ,  A61K31/445 ,  A61K31/451 ,  A61K31/4545 ,  A61P9/00 ,  A61P9/06 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  A61P9/14 ,  A61P13/12 ,  A61P25/06 ,  A61P43/00 ,  C07D211/52 ,  C07D401/12 ,  C07D471/04 ,  C07D519/00

    CPC分类号： C07D471/04 ,  A61K31/437 ,  A61K31/445 ,  C07D211/48

    摘要： PROBLEM TO BE SOLVED: To provide a therapeutic and/or preventing agent for a disease due to vascular constriction or vasodilation comprising an EDG-5 modulator EDG (Endothelia differentiation gene)-5 modulator; and also to provide a new EDG-5 antagonist.SOLUTION: A therapeutic and/or preventing agent for a disease due to vascular constriction or vasodilation comprises a EDG-5 modulator. Since EDG-5 modulator specifically binds EDG-5 and shows antagonistic or agonistic action, EDG-5 antagonist is useful for treating and/or preventing for a disease due to vascular constriction, for example, cerebrovascular spasmodic disorder after subarachnoid hemorrhage or stroke, cardiovasucular spasmodic disorder, hypertension, renal disease, cardiac infarction, cardiac angina, arrhythmia, facilitation of the portal blood pressure involved in liver cirrhosis, varicosity involved in liver cirrhosis and the like; or EDG-5 agonist is useful for treating and/or preventing for a disease due to vasodilation of blood vessels, for example, chronic headache (such as migraine, tension-type headache, mixed-type headache thereof, or migrainous neuralgia), haemorrhoid, congestive disorder and the like.

    摘要翻译： 要解决的问题：提供由于包含EDG-5调节剂EDG（内皮分化基因）-5调节剂的血管收缩或血管舒张引起的疾病的治疗和/或预防剂; 并提供新的EDG-5拮抗剂。 解决方案：由于血管收缩或血管舒张引起的疾病的治疗和/或预防剂包括EDG-5调节剂。 由于EDG-5调节剂特异性结合EDG-5并且具有拮抗作用或激动作用，因此EDG-5拮抗剂可用于治疗和/或预防由于血管收缩引起的疾病，例如蛛网膜下腔出血或中风后的脑血管性痉挛障碍 痉挛性疾病，高血压，肾脏疾病，心肌梗死，心脏心绞痛，心律失常，促进肝硬化引起的门静脉血压，涉及肝硬化的静脉曲张等; 或EDG-5激动剂可用于治疗和/或预防由于血管血管扩张引起的疾病，例如慢性头痛（如偏头痛，紧张型头痛，混合型头痛或偏头痛神经痛），痔疮 ，充血障碍等。 版权所有（C）2012，JPO＆INPIT